FENC - NASDAQ
Fennec Pharmaceuticals Inc.
$9.98
-8.4%Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
At a Glance
Live SnapshotFennec Pharmaceuticals Inc. Management Team
Mr. Terry Evans
Chief Commercial Officer
Mr. Jeffrey S. Hackman
Chief Executive Officer & Director
Compensation
$540,000
Mr. Robert C. Andrade
Chief Financial Officer
Compensation
$957,999
Dr. Pierre S. Sayad M.S., Ph.D.
Chief Medical Officer
Compensation
$325,000
Ms. Christiana Cioffi M.B.A.
Chief Strategy Officer
Mr. Mark Gowland
Controller
Mr. Lei Fang
President of Pharstat Inc
Fennec Pharmaceuticals Inc. Insider Positioning
During the last 12 months, insiders have purchased $100K and sold $13.72M worth of FENC shares, resulting in $13.62M of net selling activity.
3 Months
0
0.00
39.8K
291.34K
-291K
-$291K
3-6 Months
0
0.00
1.0M
7.74M
-7.7M
-$7.74M
6-9 Months
4.6K
11.29K
364.2K
3.11M
-3.1M
-$3.10M
9-12 Months
36.2K
88.71K
441.1K
2.58M
-2.5M
-$2.49M
Top Buyers
Raykov Rosty
Director
$100K
Top Sellers
Southpoint Capital Advisors Lp
10 Percent Owner
$10.34M
Hackman Jeffrey S.
Director, Officer: Chief Executive Officer
$2.23M
Raykov Rosty
Director
$1.06M
Rallis Chris A
Director
$85K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $13.62M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
4 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
FENC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 10, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | June 03, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | May 13, 2024 | June 25, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 12, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | May 02, 2022 | June 14, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | May 25, 2021 | June 29, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | May 11, 2020 | June 22, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | May 16, 2019 | June 18, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | May 10, 2018 | June 07, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | May 24, 2017 | June 27, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.